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Human immunodeficiency virus-associated nephrop-
athy (HIVAN) is etiologically related to the viral infec-
tion, but the mechanisms of virus-induced renal in-
jury remain undetermined. Peculiar histopathological
features of HIVAN are the enhanced proliferation and
the loss of differentiation markers of glomerular ep-
ithelial cells (podocytes). We found that podocytes
were not permissive to HIV-1 replication. In this study
we investigated the effects of the HIV-1 regulatory
protein Tat on primary cultures and on a continuous
line of podocytes. Our results demonstrated that Tat
induced hyperproliferation of these cells in a dose-
dependent manner. This activity was primarily medi-
ated by the basic domain of the viral protein. Proteogly-
cans were required for this phenomenon because Tat-
induced increase of podocyte growth was significantly
impaired by inhibition of proteoglycan synthesis with
-D-xyloside. In podocyte cultures Tat promoted both
the transcription and the release of basic fibroblast
growth factor, which contributed to the enhanced cell
proliferation. Moreover, Tat deregulated the podocyte
phenotype causing down-regulation of maturity mark-
ers such as WT-1 and synaptopodin, alteration of cyto-
architecture, and impairment of permselectivity.
Together, these results demonstrate that the interac-
tion of extracellular Tat with podocytes can induce
alterations that mimic the pathological changes of
podocytes detected in HIVAN. (Am J Pathol 2002,
161:53–61)
A relevant increase in kidney disease incidence has
been recently reported in human immunodeficiency virus
(HIV)-infected patients.1 HIV-associated nephropathy
(HIVAN) is the prominent renal complication of HIV infec-
tion, characterized by heavy proteinuria and progressive
renal failure with severe prognosis.2,3 If untreated, HIVAN
may progress to end-stage renal disease in few months.
In African-American adults, HIVAN is the third leading
cause of end-stage renal disease.1 HIVAN is considered
a pan-nephropathy2 characterized, on the pathological
point of view, by a collapsing form of glomerulosclerosis
associated with severe tubulointerstitial injury (microcys-
tic dilatation and apoptotic changes of tubuli and mono-
nuclear infiltration). It has been recently shown that glo-
merular lesions of HIVAN involve striking alterations of
glomerular epithelial cells (podocytes), which include hy-
perplasia and dysregulation of mature podocyte pheno-
typic markers.4 Clinical and experimental data indicate
that HIVAN is etiologically related to HIV infection, but the
pathogenesis of virus-induced renal injury is not clearly
understood.5 We recently reported that tubular epithelial
cells and glomerular mesangial cells (MCs) could sustain
viral productive replication with distinct pathological ef-
fects that mimic the alterations detected in HIVAN. In
cultured tubular epithelial cells, HIV-1 caused apopto-
sis,6 whereas in MCs HIV-1 established persistent infec-
tion and stimulated the synthesis of cytokines involved in
the pathogenesis of glomerulosclerosis.7 Conversely,
podocytes were not permissive to virus replication, pos-
sibly because they did not express HIV-1 receptors.7 A
HIVAN-like disease characterized by podocyte dysregu-
lation occurred in transgenic mice with intrarenal expres-
sion of gag-pol-deleted HIV provirus. In these transgenic
mice the synthesis of unspliced and multiply spliced viral
regulatory proteins (Tat, Rev, and Nef) occurred in renal
cells in the absence of a productive viral replication.8,9
Thus, podocyte alterations could be caused by the ex-
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pression of these viral proteins. In the present study, we
investigated the effects of Tat on human cultured podo-
cytes. HIV-1 Tat is a transactivating factor of 86 to 101
amino acids, which is encoded by two exons and is
translated from multiply spliced 2-kb mRNAs.10 Tat is
essential for HIV-1 replication and it is released by HIV-
infected cells, as demonstrated by the detection of Tat in
the sera of HIV patients.11,12 Extracellular Tat exerts
pleiotropic effects on uninfected cells either entering into
the cells or interacting with cell-surface receptors. In fact,
Tat has been shown to stimulate proliferation, migration,
and production of growth factors and cytokines in several
cell types.13–16 Tat can also elicit apoptotic effects on T
cells and neurons12,17,18 whereas it may induce cell sur-
vival in other cell types such as endothelial and Kaposi’s
sarcoma cells.19 Remarkably, Tat can induce opposite
effects (promotion versus inhibition) on cell survival on the
same cell type, depending on its concentration.11 Thus,
there is an increasing body of evidence for the role of
extracellular Tat in AIDS-associated immune dysfunction
and pathological manifestations.20 Herein we report that
HIV-1 Tat affects the podocyte phenotype and functions
inducing cell proliferation, down-regulation of mature
phenotypic markers, and alteration of cytoarchitecture.
Materials and Methods
Reagents
Reagents were obtained from the following sources: HIV-1
Tat, rabbit anti-Tat serum from Intracel (London, UK); [11-
24], [46-60] Tat peptides from Neosystem (Strasbourg,
France); [61-86] Tat peptide from Tecnogen (Piana di
Monte Verna, Italy); monoclonal antibody (mAb) against
Ki-67 antigen, biotinylated anti-mouse IgG, biotinylated anti-
rabbit IgG, and peroxidase-conjugated streptavidin from
DAKO (Glostrup, Denmark); mAb anti-synaptopodin, (kindly
provided by Dr. P. Mundel, Division of Nephrology, Albert
Einstein College of Medicine, Bronx, NY, USA); anti-
Wilms’ tumor antigen (WT-1) rabbit polyclonal Ab, anti-
Flk-1 rabbit polyclonal Ab, and anti-Flt-1 rabbit polyclonal
Ab from Santa Cruz Biotechnology (Santa Cruz, CA);
mAb anti-basic fibroblast growth factor (bFGF) from R&D
(Minneapolis, MN); mAb anti-human integrin 31, mAb
anti-human integrin v3, and mAb anti-human integrin
1 from Chemicon Int. (Temecula, CA); fluorescein iso-
thiocyanate (FITC)-conjugated goat anti-mouse and anti-
rabbit IgG, FITC-labeled phalloidin, -D-xyloside, (2,3-
bis[2-methoxy-4-nitro-5-sulfophenyl]-2H-tetrazolium-5-
carboxy-anilide inner salt) sodium salt (XTT), and other
immune reagents and chemicals were from Sigma Chem-
ical Co. (St. Louis, MO), unless otherwise specified. Tis-
sue culture media were from Euroclone (Paignton, UK) and
fetal calf serum (FCS) from Hyclone (Logan, UT); molecular
biology reagents were from Perkin-Elmer Cetus (Norwalk,
CT); plastic-ware from Falcon (Becton-Dickinson, San
Jose, CA).
Preparation of Human Glomerular Cells
Primary cultures of glomerular mesangial and epithelial
cells were established as described.21 Briefly, decapsu-
lated glomeruli were isolated by differential sieving from
renal cortex fragments taken from surgically removed
kidneys of six Caucasian patients, treated with collage-
nase and seeded in Dulbecco’s modified Eagle’s me-
dium (DMEM) containing 20% FCS and D-valine. After 2
weeks MCs were collected by digestion with trypsin-
ethylenediaminetetraacetic acid and grown in DMEM-
10% FCS. Cultured cells were characterized according to
established criteria.21–23 Primary cultures of podocytes
were obtained by plating at high-density glomeruli un-
treated with collagenase. After a 10 day-incubation in
DMEM-20% FCS, the cultures were trypsinized and the
outgrowing podocytes were expanded. Phenotypic char-
acterization was performed according to cell morphology
(polyhedral cells with cobblestone-like appearance);
positive staining for synaptopodin, WT-1, cytokeratins,
vimentin, and laminin; negative staining for smooth mus-
cle-type myosin, FVIIIr:Ag, and CD45; and cytotoxicity in
response to 50 g/ml of puromycin aminonucleoside.
Established lines of differentiated MCs and podocytes
were obtained by infection of pure primary cultures with a
hybrid Adeno5/SV40 virus, as described.21 Individual
foci of immortalized cells were subcultured and cloned.
The selected clones were used between passages 30
and 45. The podocyte line was characterized according
to the phenotype, following the criteria mentioned above.
Cell Growth Assays
MCs and podocytes of primary cultures and continuous
lines were seeded at the concentration of 2  104 cells/
cm2 and rested for 5 hours in DMEM-2% FCS. Then, the
cells were washed and stimulated with different doses of
Tat (0.2 to 200 ng/ml) in medium containing 0.1% bovine
serum albumin (BSA). To evaluate the kinetics of the cell
growth, the cultures were incubated in medium without
phenol red containing 200 g/ml of XTT and 0.2% phena-
zine methosulphate and the absorbance at 450 nm was
monitored at different times.24 The results were con-
firmed by viable cell counting with the Trypan blue ex-
clusion test. Podocyte proliferation was also measured by
the [3H]-thymidine uptake method. Each culture condi-
tion was tested in triplicate incubating the cells for 48
hours in 96-well plates as described. During the last 6
hours 1 Ci/well of [3H]-thymidine (Amersham Pharmacia
Biotech, Little Chalfont, UK) was added to the cultures.
The harvested samples were processed for -scintillation
counting.
Experiments were performed by stimulating podocytes
with Tat peptides at concentrations equimolar to those of
Tat protein. Proliferation tests were also performed by
plating podocytes into 96-well plates coated with Tat [1
g/ml in phosphate-buffered saline (PBS), pH 7.4, for 12
hours at 4°C]. After washing the plates with PBS, the
podocytes were seeded at the usual concentration and
their growth was evaluated as described. Blocking ex-
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periments were done by preincubating podocyte cultures
with antibodies (Abs) specific to surface molecules (5
g/ml in DMEM-0.1% BSA for 1.5 hours at 37°C). To
inhibit the synthesis of proteoglycans, -D-xyloside (25
mmol/L) was added to podocyte cultures 24 hours before
stimulation with Tat or Tat peptides. To evaluate the in-
fluence of soluble factors in Tat-induced hyperprolifera-
tion, podocyte cultures were stimulated with 10 ng/ml of
Tat for 1 hour at 37°C or incubated with medium alone,
washed for three times and then incubated with DMEM-
0.1% BSA. After a 24-hour incubation the supernatants of
Tat- and mock-stimulated cultures were taken and cen-
trifuged at 15,000 rpm for 15 minutes at 4°C, then the
media were absorbed overnight at 4°C into microtiter
plates coated with anti-bFGF mAb (10 g/ml in PBS pH
7.4 for 12 hours at 4°C) or with anti-Ki67 mAb, used as
control antibody. Podocyte cultures were incubated for
24 hours at 37°C with 50% DMEM-0.1%BSA and 50%
conditioned media. Cell proliferation was evaluated by
viable cell counting and the XTT assay.
Immunostaining Studies
Podocytes were cultured in chamber slides and stimu-
lated with 10 ng/ml of Tat. After a 24-hour incubation the
cells were fixed with cold methanol for 15 minutes and
washed with PBS. The monolayers were incubated with 1
g/ml of anti-Ki-67 mAb for 1 hour at room temperature,
washed in PBS, stained with FITC-conjugated goat anti-
mouse IgG, and examined with an epifluorescence mi-
croscope. Control experiments included incubation of the
cells with irrelevant mouse isotypic Igs or omission of
primary Abs followed by the appropriate labeled second-
ary Abs. Immunoperoxidase tests were performed on
podocyte cultures fixed in 3.5% paraformaldehyde for 15
minutes at room temperature. The monolayers were in-
cubated with 3% hydrogen peroxide to quench endoge-
nous peroxide activity and with PBS-1% BSA to prevent
aspecific reactions. Then, the specimens were incubated
with primary Abs (2 g/ml of anti-WT-1 Igs; 1:10 diluted
supernatant of hybridoma specific to synaptopodin; 2
g/ml of irrelevant mouse and rabbit isotypic Igs) for 1
hour at room temperature After washing with Tris-buff-
ered saline, pH 7.4, and 2% Triton X-100, the cells were
incubated at room temperature for 10 minutes with bio-
tinylated anti-mouse or anti-rabbit Igs and then for 10
minutes with streptavidin conjugated to horseradish per-
oxidase. The specimens were stained with 0.03% benzi-
dine and counterstained with hematoxylin and eosin.
The expression of integrins (31, v3, 1) and
vascular endothelial growth factor (VEGF)-receptors
(VEGFRs: Flk-1, Flt-1) in podocytes was evaluated by
flow cytometry. Briefly, 106 cells were incubated for 30
minutes at room temperature with 1 g of the specific Ab
and then with FITC-labeled goat anti-mouse or anti-rabbit
IgG. After washings with PBS, the cells were analyzed
(FACScan, Becton Dickinson).
Cell Cytoskeleton Studies
Cytoskeleton alterations were studied on fixed podocytes
after permeabilization with 0.1% Triton X-100 in PBS and
stained for F-actin with 2 g/ml of FITC-conjugated phal-
loidin. The modification of podocyte shape was moni-
tored as described.25 The cells were plated in a hermet-
ically sealed Plexiglas Nikon NP-2 incubator (Nikon Co.,
Tokyo, Japan) at 37°C, rested for 5 hours with medium
containing 2% FCS, stimulated with Tat (1 to 10 ng/ml)
and then observed throughout a 2-hour period by Nikon
Diaphot inverted microscope with a 10 phase-contrast
objective. The imagines were recorded by a JVC-1CCD
video camera (video card Targa 2000; Truevision, Santa
Clara, CA) and evaluated by MicroImage-analysis sys-
tem (Casti Imaging, Venice, Italy).
Permeability Assay
Podocytes were seeded on polycarbonate filters (pore
size, 0.4 m) of Transwell chambers (Costar, Cambridge,
MA) at the concentration of 1.5  105/well in DMEM-2%
FCS. The permeability of the monolayers was measured
by diffusion of Trypan blue-albumin complexes.26 After
overnight incubation, 0.2 ml of medium without phenol
red and FCS were added in the upper chamber and the
cells were stimulated for 1 hour at 37°C with 10 ng/ml of
Tat. Then, the upper chamber was filled with 0.3 ml of
DMEM-200 mmol/L Trypan blue-albumin. The chambers
were incubated at 37°C with continuous agitation. After 5
minutes the monolayers showing leakage of dye were
discarded. Transport of albumin across monolayers was
determined by sampling aliquots at different times (15 to
120 minutes) and measuring absorbance at 590 nm in
the outer and inner wells in duplicate.26
Analysis of bFGF Synthesis by Podocytes
The expression of bFGF was assessed by reverse tran-
scriptase-polymerase chain reaction (PCR) using total
RNA taken from untreated or Tat-stimulated podocytes.
cDNA was synthesized by priming RNA (1, 0.1, or 0.01
g) with oligo-dT (Clontech). PCR was performed using
30 pmol/L of mRNA-specific primers (forward 5GGCT-
TCTTCCTGCGCATCC3; reverse, 5CCGTACTTTGCTT-
GACCCG3) synthesized by Genset (Paris, France). 27
PCR was performed for only 20 cycles (30 seconds at
94°C, 30 seconds at 57°C, and 30 seconds at 72°C) to
detect amplicons of bFGF transcripts (283 bp) under
conditions of linear amplification.21 The production of
bFGF by podocytes was evaluated by measuring the
bFGF content of podocyte culture supernatants, taken in
different experimental conditions, by a commercial en-
zyme-linked immunosorbent assay kit following the man-
ufacturer’s recommendations (R&D Systems, Minneapo-
lis, MN).
Statistical Analysis
All data are given as mean values  SD. Differences
among multiple groups were evaluated by one-way anal-
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ysis of variance in combination with Tukey’s multiple
comparison test. A P value of 0.05 was considered
significant.
Results
HIV-1 Tat Enhanced Proliferation of Podocytes
The treatment of podocytes with exogenous Tat induced
a relevant increase of cell proliferation. Figure 1 shows
the time-dependent increase in cell proliferation of a con-
tinuous line of podocytes after stimulation with Tat at 2
ng/ml. This Tat concentration is comparable to that de-
tected in sera of AIDS patients.12 Tat also stimulated the
growth of MCs, but to a lower extent. Similar results were
obtained with primary cultures of podocytes and MCs
derived from six different donors (data not shown). The
proliferative effect of Tat was also detected by [3H]-
thymidine uptake assay (data not shown). The Tat-in-
duced proliferation was dose-dependent and occurred at
a concentration of Tat as low as 0.2 ng/ml (Figure 2).
Heat-treated or neutralized Tat was inactive, demonstrat-
ing the specificity of the observed phenomenon. The
neutralization of Tat was performed by preincubation with
the specific Ab (5 g/ml for 1 hour at 37°C): the addition
of Ab alone did not affect podocyte growth (not shown).
By detection of Ki-67 antigen, a nuclear protein ex-
pressed by all proliferating cells, a striking increase of the
number of cycling cells was observed after the treatment
with Tat (vehicle alone, 15 7%; Tat, 90 5%; Figure 3).
To elucidate the mechanisms of Tat activity, we tried to
identify the protein domains required for this phenome-
non. Cell growth experiments were performed using the
basic [46-60] peptide and the [61-86] peptide that en-
compasses the RGD region of Tat. The [11-24] peptide
considered biologically unrelevant was used as con-
trol.28 As shown in Figure 4, the results indicated that the
basic domain of Tat exerted the prominent effect in en-
hancing podocyte proliferation, but also the RGD region
contributed to the activity of the whole protein, as shown
by the additive effect obtained by incubating cells with
both [46-60] and [61-86] peptides. In contrast, the [11-
24] peptide was ineffective on cell proliferation.
Figure 1. Tat-induced increase in the proliferation of glomerular cells. Con-
tinuous lines of podocytes and MCs were stimulated with Tat (2 ng/ml) and
incubated in DMEM-0.1% BSA. Cell proliferation was assessed by measuring
at 450 nm absorbance the culture medium after bioreduction of XTT, in three
independent experiments each in triplicate. The results are expressed as the
percentage of cell proliferation in comparison with that of untreated cell
cultures at 48 hours of incubation, corresponding to the maximum prolifer-
ation rate detected in preliminary experiments. Viable cells were counted by
Trypan blue exclusion staining. After a 48-hour incubation the number of
podocytes increased from 2  104 cells/cm2 up to 4  104/cm2 or 8.5 
104/cm2 on average, in the absence or presence of Tat, respectively.
Figure 2. Dose-dependence of the increase of podocyte growth induced by
Tat. The results are expressed as the percentage of cell proliferation in
comparison with that of untreated cell cultures. Cell growth evaluation was
performed after a 48-hour incubation with the XTT assay in five independent
experiments, each in triplicate. Similar results were obtained by viable cell
counting (100% increase  increase from 3  104 cells/cm2 to 5.5  104
cells/cm2, on average).
Figure 3. Expression of the proliferation marker Ki-67 in podocytes after a
24-hour incubation. In cultures of untreated podocytes (top) the average
number of Ki-67-positive cell cycle-engaged cells was 15  7% of the cells
incubated in DMEM-0.1% BSA. After treatment with 10 ng/ml of Tat (bot-
tom), 90  5% of the cultured podocytes expressed the Ki-67 nuclear
antigen. Original magnification, 400.
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Proteoglycans Were Required for Tat-Induced
Increase of Podocyte Proliferation
To evaluate whether Tat stimulated podocytes as a result
of surface receptor interaction or as a consequence of its
internalization, podocyte proliferation was studied by
seeding the cells on 96-well plates coated with Tat.
After a 48-hour incubation, immobilized Tat stimulated
cell proliferation in a way comparable to that of soluble
Tat (immobilized Tat, 265  35% increase; 10 ng/ml
Tat, 290  30% increase). With other cell types Tat has
been shown to modulate cell functions by engaging
integrins or VEGFRs via its RGD and basic regions,
respectively.13,15,29 By cytofluorimetric analysis podo-
cytes expressed 31 and v3 integrins and VEGFR-1
and -2 (data not shown). Therefore, experiments with
specific blocking Abs were performed to evaluate the
involvement of these cell receptors in Tat-induced hyper-
proliferation of podocytes. As shown in Figure 5, pretreat-
ment of podocytes with both anti-VEGFR-1 and -2 Abs, at
concentrations previously shown to block proliferation of
endothelial cells,30 did not inhibit proliferation of podo-
cytes induced by [46-60] Tat peptide. Conversely, anti-
integrin Abs significantly reduced the activity of [61-86]
peptide (Figure 5).
It is known that HIV-1 Tat protein binds to heparan
sulfate proteoglycans (HSPGs) of the cell surface and
extracellular matrix.31,32 Figure 6 shows that the treat-
ment of podocytes with -D-xyloside, an inhibitor of pro-
teoglycan biosynthesis,33 caused a significant reduction
of Tat-induced cell proliferation. Remarkably, similar re-
sults were obtained by using [46-60] peptide. In contrast,
-D-xyloside did not affect proliferation induced by [61-
86] peptide or basal proliferation of podocytes. This sug-
gests that the interaction of Tat basic domain with pro-
teoglycans plays a key role in Tat-induced biological
activity on podocytes.
bFGF Synthesis Stimulated by Tat Is Involved in
Tat-Induced Podocyte Proliferation
Numerous studies have implicated bFGF in the patho-
genesis of kidney disease as a mitogenic factor for
renal cells.34,35 bFGF has been also involved in Tat-
induced proliferation of endothelial and Kaposi’s sar-
coma cells.36,37 Thus, we evaluated the possible role of
this growth factor in our experimental model. We found
that both primary and immortalized cultures of podocytes
Figure 4. Evaluation of the involvement of different Tat domains in podocyte
hyperproliferation. The experiments were performed by using Tat (10 ng/ml)
or equimolar concentrations of Tat peptides: [11-24] Tat and [46-60] Tat
including the basic domain [61-86] Tat encompassing the RGD region. The
data (from five experiments, each in triplicate) refer to the percentage of cell
growth after a 48-hour incubation in comparison with that of untreated cells.
Podocyte growth was evaluated by the XTT assay (by viable cell counting,
100% increase  increase from 4  104 cells/cm2 to 7.5  104 cells/cm2, on
average).
Figure 5. Evaluation of the involvement of different cell-surface molecules in
podocyte hyperproliferation promoted by Tat peptides. Podocytes were
preincubated with vehicle alone or with 5 g/ml of Abs specific to integrins
(Abs anti-31  anti-v3  anti-1) and/or to VEGFRs (Abs anti-Flk-1 
anti-Flt-1) for 1.5 hours at 37°C and then stimulated with [46-60] Tat peptide
(2 ng/ml) or [61-86] Tat peptide (2.5 ng/ml). The data (from three experi-
ments, each in triplicate) were evaluated by the XTT assay. The results are
expressed as the percentage of cell proliferation in comparison with that of
untreated cell cultures after a 48-hour incubation. By viable cell counting,
100% increase of podocyte growth was equivalent to an increase from 3.9 
104 cells/cm2 to 7.8  104 cells/cm2, on average.
Figure 6. Evaluation of the involvement of proteoglycans in Tat-induced
podocyte hyperproliferation. Cultures of podocytes untreated (white col-
umns) or treated with 25 mmol/L of -D-xyloside (black columns) were
incubated in the presence of absence of Tat (10 ng/ml) [46-60], Tat peptide
(2 ng/ml), or [61-86] Tat peptide (2.5 ng/ml). The data (from three experi-
ments, each in duplicate) were evaluated by XTT assay and expressed as
percentage of cell proliferation in comparison with the values obtained with
the untreated podocytes after a 48-hour incubation.
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produced low levels of bFGF (10 to 20 pg/ml). Podocyte
stimulation with Tat for 24 hours promoted an increased
expression of specific mRNA and a concomitant bFGF
release (140 to 150 pg/ml), suggesting an enhanced
bFGF synthesis (Figure 7). However, because increased
levels of bFGF (40 to 45 pg/ml) were detected also in
podocyte cultures pulsed for 1 hour with Tat, it is con-
ceivable that a retrieval of preformed bFGF may also
concur. The later mechanism may be because of either
the release of intracellular store of bFGF or to its mobili-
zation from the cell surface. It is known that up to 30% of
the synthesized bFGF binds to cell-surface and extracel-
lular matrix-associated HSPGs.31,38 The basic region of
Tat can displace preformed HSPG-bound bFGF by com-
peting for heparin-binding sites.31 Indeed, an augmented
concentration of bFGF in the culture supernatants (33 to
39 ng/ml) was observed when podocytes were treated
with 30 g/ml of heparin, in the absence of an enhanced
mRNA transcription monitored by reverse transcriptase-
PCR. The increase of cell proliferation also detected in
the latter experimental conditions (not shown) remarked
the possible role of bFGF in podocyte proliferation. In-
deed, when podocytes were incubated with the condi-
tioned media of Tat-treated podocytes, an enhanced cell
growth was observed (170  15% after a 24-hour incu-
bation, assumed as 100% the growth of untreated podo-
cytes). The absorption of conditioned media on plates
coated with anti-bFGF mAb, but not with an irrelevant
mAb, caused a significant reduction of the proliferative
activity (120  11% in the same experimental conditions,
P  0.01).
Tat Induced Dysregulation and Functional
Alterations of Podocytes
Glomerular pathology of HIVAN is characterized by de-
regulated podocyte phenotype with morphological alter-
ations of podocyte cytoarchitecture and loss of specific
markers of mature podocytes, such as WT-1 and synap-
topodin.39,40 The stimulation of podocytes with Tat
caused a relevant impairment of the expression of syn-
aptopodin in cultured cells after a 24-hour incubation
(Figure 8). Similar results were obtained testing WT-1
positivity in the same experimental conditions (data not
shown). Because of the association of synaptopodin with
the cytoskeleton, we investigated the effect of Tat onto
podocyte cytoskeletal organization. We observed changes
of the podocyte shape early after exposure of the cells to
10 ng/ml of Tat (Figure 9). In the same experimental
conditions, modifications of the normal distribution of ac-
tin-containing stress fibers were revealed. After a 2-hour
incubation of podocytes with Tat, stress fibers tended to
rearrange, retract, and depolymerize (Figure 10). In all
these experiments the viability of treated podocytes did
not vary from that of untreated (90 to 95%). Tat-induced
alterations were reversible after washing and culturing
podocytes for 24 hours (not shown).
Because the cytoarchitecture of podocytes influences
glomerular permselectivity,39 we tested the possibility
that Tat could alter this function by evaluating its effect on
the permeability to albumin of podocyte monolayers. The
results indicated that after a 1-hour incubation, the diffu-
sion of Trypan blue-albumin complexes through podo-
cyte monolayers treated with 2 ng/ml of Tat was doubled
(absorbance of 630  35 at 590 nm in the inner wells) in
Figure 7. Reverse transcriptase-PCR analysis of bFGF-mRNA expression in
untreated and Tat-stimulated podocytes. RNA samples were taken from
untreated (lane 1, 1 g; lane 3, 0.1 g; lane 5, 0.01 g) and Tat-treated
podocytes (lane 2, 1 g; lane 4, 0.1 g; lane 6, 0.01 g) after a 24-hour
incubation. The figure shows amplicons obtained with 20 PCR cycles to
compare the amounts of specific transcripts under conditions of linear am-
plification (DNA size markers, 50- to 2000-bp ladder; Sigma).
Figure 8. Expression of the differentiation marker synaptopodin in podo-
cytes. A: Expression of synaptopodin in untreated podocytes. B: Reduction
of staining for synaptopodin in podocytes treated with 10 ng/ml of Tat for 24
hours. Original magnification, 400.
Figure 9. Micrographs representative of the shape change of podocytes as
observed by comparison of time 0 (A and C) and 1-hour frames (B and D).
A and B: Podocytes stimulated with 10 ng/ml of Tat and incubated at 37°C in
DMEM-0.1% BSA. The arrows indicate cells with modified shape. C and D:
Untreated podocytes in the same experimental conditions. The micrographs
were obtained by time-lapse analysis of podocyte shape modification per-
formed by digital saving of imagines at 15-minute intervals. Three experi-
ments were performed with similar results. Original magnification, 100.
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respect to that of untreated cultures (absorbance of
295  42).
Discussion
Podocytes are specialized cells with essential functions
in renal glomerular physiology.39,41 Podocyte differentia-
tion is characterized by the block of cell proliferation
associated with the expression of cyclin D1, cyclin-de-
pendent kinase inhibitors, and distinctive markers such
as WT-1 and synaptopodin.42 Primary podocyte injury
has been indicated to cause certain forms of focal seg-
mental glomerulosclerosis, but the nature of the damage
is unknown.43,44 Glomerulopathy of HIVAN is mainly rep-
resented by severe focal segmental glomerulosclerosis
with peculiar alterations of podocytes (hyperproliferation,
loss of maturity markers, and cytoarchitecture chang-
es).2,4 Clinical studies have recently shown that HIV
infection of the kidney is etiologically related to the de-
velopment of nephropathy.45,46 Experimental findings
demonstrated that pathological features of HIVAN could
be caused by virus infection of the renal cells or by their
exposure to HIV proteins.5–9 However, the direct effects
of HIV-1 on podocytes are still undetermined. It has been
previously shown that podocytes are not permissive to
HIV-1 replication,7,47 probably because of the lack of
virus receptors.7 In the present study we show that HIV-1
Tat induced changes on cultured human podocytes sim-
ilar to those detected in HIVAN. Tat protein is a powerful
transcriptional activator of the viral gene expression re-
quired for HIV replication. Tat also induces pleiotropic
effects on different cell types, mainly transactivating spe-
cific cellular genes or acting as a secreted growth fac-
tor.13–16 Indeed, Tat can be released and enter cells
freely, or it can interact with cell-surface molecules acti-
vating various signaling pathways.28 In this study we
found that extracellular Tat enhanced proliferation of
podocytes in a dose-dependent manner. Of note, this
effect occurred also at a concentration of Tat similar to
that detected in sera of infected patients.12 After stimu-
lation with Tat, podocytes showed an enhanced expres-
sion of the proliferation marker Ki-67 and a disappear-
ance of the differentiation markers such as synaptopodin
and WT-1. This evidence is consistent with the his-
topathological changes4 and the cell cycle re-entry of
podocytes observed in HIVAN glomerulopathy.42–44
Extracellular Tat has been found to mimic both matrix
molecules via its RGD region (C-terminal sequence,
amino acids 73 to 86) and angiogenic growth factor
through its basic domain (amino acids 46 to 6028). We
report herein that Tat activity on podocytes was exerted
through its interaction with cell-surface molecules rather
than its internalization because the proliferative activity
was retained by immobilized Tat. Both peptides contain-
ing basic and RGD domains contributed to the Tat-in-
duced increase of podocyte proliferation as shown by the
concomitant stimulation with these peptides. However,
the prominent effect was accounted to the basic domain.
Preincubation with blocking Abs demonstrated that the
effect of [61-86] Tat peptide was dependent on the inter-
action with integrins, whereas that of [46-60] Tat peptide
could not be related to the engagement of VEGFR-1 and
-2 receptors. Moreover, we found that Tat-induced in-
crease of podocyte growth was significantly impaired by
the inhibition of proteoglycan biosynthesis. It has been
recently proved that cell-membrane HSPGs may interact
with the extracellular Tat.48 Tat binds to the negatively
charged sulfate groups of HSPGs through its arginine-
rich basic domain.31 Indeed, HSPGs are present on the
surface and in the extracellular matrix of podocytes, and
play a role in the pathophysiology of the glomerular
cells.49 Thus, the interaction of Tat via its basic region
with HSPGs may be critical to promote podocyte prolif-
eration. This interaction could also represent a novel
target for therapeutic intervention in HIV infection. In fact,
the use of polysulfated compounds blocking the basic
domain of Tat, such as suramin, has been shown to
antagonize Tat activity and synergize with other anti-HIV
drugs.50 Moreover, HSPGs are known to play a critical
role in glomerular permselectivity.49 Therefore, Tat inter-
action with podocyte HSPGs may affect the function of
these cells in the regulation of glomerular permeability.
Indeed, Tat significantly enhanced albumin translocation
in vitro across the podocyte monolayer.
We found that extracellular Tat increased bFGF re-
lease in podocyte cultures both by enhancing the syn-
thesis of specific mRNA and mobilizing the sequestered
growth factor. Our data also indicated that bFGF was
involved, at least in part, in Tat-induced proliferation of
podocytes, as previously seen in other cell types.36,37 A
body of evidence indicates that bFGF is implicated in the
pathogenesis of renal disease, because it is mitogenic for
both MCs and proximal tubular epithelial cells and stim-
ulates MC extracellular matrix production.34,35 Recent
studies demonstrated that bFGF also has a proliferative
effect on podocytes and that it is involved in the devel-
opment of segmental glomerulosclerotic lesions.51,52 In-
terestingly, increased expression of bFGF was shown in a
transgenic model of HIVAN,53 and high levels of bFGF
were detected in the kidneys of HIV-infected children.54
Our results suggest that the production of bFGF in the
glomeruli of the HIV-1-infected patients may be triggered
by Tat.
Figure 10. F-actin distribution in podocytes. A: F-actin distribution in fixed
and permeabilized podocytes after incubation for 2 hours at 37°C. B: F-actin
distribution in podocytes stimulated with 10 ng/ml of Tat for 2 hours at 37°C.
Five experiments were performed with similar results. Original magnifica-
tion, 400.
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The complex functions of podocytes depend on a
highly differentiated and unique cytoarchitecture.39 We
found that Tat caused alteration of the podocyte cytoskel-
eton associated with a rapid modification of cell shape.
Moreover, Tat caused a reduced expression of synap-
topodin, a proline-rich actin-associated protein that influ-
ences the actin-based shape and motility of podocyte
foot processes.40 Such alterations of cytoskeleton may
explain the observed increase of the podocyte monolayer
permeability induced by Tat at a concentration detect-
able in HIV patients. Because HIVAN is a clinicopatho-
logical entity characterized by heavy proteinuria, Tat may
contribute to the enhanced glomerular permeability.
The potential relevance of Tat in the pathogenesis of
HIVAN is strengthened by the immunohistochemical de-
tection of Tat protein in the glomeruli and tubules of
HIVAN biopsies, but not in other primary glomerular dis-
eases occurring in HIV-infected patients.55 Beside exper-
imental studies,6,7 clinical observations indicated that re-
nal cells of HIVAN patients can harbor replicating virus
and might function as a viral reservoir.45,46 Thus, Tat
released from infected renal cells in the glomerular mi-
croenvironment may cause the podocyte injury associ-
ated with HIV glomerulopathy.2 Moreover, being that Tat
is a low-molecular weight protein it is conceivable that Tat
present in the plasma of HIV-infected patients12 may filter
through the glomerular capillary walls reaching podo-
cytes.
In conclusion, we found that HIV-1 Tat can induce in
vitro alterations of podocyte proliferation and differentia-
tion similar to those detected in vivo in HIVAN. The inter-
action of Tat basic domain with cell-surface HSPGs and
the increase of bFGF levels in podocytes seem to be
critical events in this phenomenon. Based on our results
we hypothesize that Tat-induced podocyte injury may
contribute to the development of the glomerular lesions in
HIVAN. Further studies aimed to elucidate the molecular
mechanisms activated by Tat on podocytes might allow
the development of novel therapeutic strategies to pre-
vent the progression of this severe renal disease.
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